Financials
MDxHealth® operates on a calendar basis with its accounting year ending on December 31.
The company reports its consolidated financial statements under International Financial Reporting Standards (IFRS) and all amounts are in US Dollars. MDxHealth publishes a consolidated and audited Annual Report on an annual basis, a consolidated Interim Report for its June 30 half-year financial figures, and business/financial updates at the end of Q1 and Q3.
Furthermore, for the Annual General Shareholders’ Meeting, the company also publishes the non-consolidated Belgian-GAAP financial statements of the parent company. Prior to October 5, 2010, MDxHealth operated under the name OncoMethylome Sciences
2021 Reporting Calendar
- March 3, 2021: Publication of FY2020 results
- April 21, 2021: Q1-2021 business update
- May 27, 2021: Annual general shareholders’ meeting
- August 26, 2021: Publication of H1-2021 results
- October 21, 2021: Q3-2021 business update
3-year Snapshot
In “000” of USD
| Profit & Loss | 2020 | 2019 | 2018 |
|---|---|---|---|
| Revenues | 18,460 | 11,785 | 28,397 |
| Gross Profit | 8,044 | 30 | 16,745 |
| Research & Development Expenses | -4.543 | -8,897 | -4,280 |
| Selling & Marketing Expenses | -16,752 | -17,809 | -29,591(1) |
| General & Administrative Expenses | -13,990 | -15,196(1) | -15,207(1) | Other Operating (Expense)/Income | 118 | -197 | 235 |
| Operating Loss | -27,123 | -43,169 | -32,098 |
| Financial Expense, Net | -1,539 | -506 | -393 |
| Loss Before Income Tax | -28,662 | -43,675 | -32.491 |
| Income Tax | 0 | 574 | 41 |
| Loss for the Year | -28,662 | -43,100 | -32,450 |
(1) The comparative figures for 2018 have been reclassed to reflect the breakdown of Selling, General and Administrative Expenses into General and Administrative Expenses and Selling and Marketing Expenses. (2) 2017 figures are the aggregate of Selling, General and Administrative Expenses.
Assests
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Total Non-Current Assets | 8,765 | 9,721 | 17,613 |
| Total Current Assets | 23,091 | 30,907 | 47,863 |
| Of Which Cash & Cash Equivalents | 15,953 | 22,050 | 26,203 |
| Total Assets | 31,856 | 40,628 | 65,476 |
Liabilities and Shareholders’ Equity
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Total Equity | 5,849 | 19,724 | 52,117 |
| Non-Current Liabilities | 12,986 | 10,477 | 1,882 |
| Current Liabilities | 13,021 | 10,427 | 11,477 |
| Total Equity & Liabilities | 31,856 | 40,628 | 65,476 |
Cash Flows
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Operating Cash Flow | -20,131 | -22,289 | -28,543 |
| Investing Cash Flow | -537 | -73 | -1,345 |
| Financing Cash Flow | 14,954 | 17,965 | 41,672 |
| Cash & Cash Equivalents at End of Period | 15,953 | 22,050 | 26,203 |
Financial Reports
2019
2018
2017
Full year 2017 Non Consolidated Statutory Account: français
Auditors Opinion: english | français
Board Report on 2017 Financial Statements “after correction to take into account a clerical drafting error”: english | français
2017 Consolidated figures: english
